Mizuho Reiterates Buy on Arcus Biosciences, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Mara Goldstein has reiterated a 'Buy' rating on Arcus Biosciences (NYSE:RCUS) and maintained a price target of $51.
October 03, 2023 | 2:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst has reiterated a 'Buy' rating on Arcus Biosciences and maintained a price target of $51.
The reiteration of a 'Buy' rating by a Mizuho analyst and the maintenance of a $51 price target indicates a positive outlook for Arcus Biosciences. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100